LC-MS Bioanalysis of Ester Prodrugs and Other Esterase Labile Molecules

Handbook of LC-MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations

Volumn , Issue , 2013, Pages 429-445

  Li, Wenkui ^a   Fu, Yunlin ^a   Flarakos, Jimmy ^a   Zhang, Duxi ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Dried blood spots; Enzyme inhibitors; Ester prodrugs; Esterase labile molecules; Incurred sample reanalysis; PH control; Stability assessment

Indexed keywords

BLOOD; ENZYME INHIBITION; MOLECULES; PLASMA STABILITY; SYSTEM STABILITY;

DRIED BLOOD SPOTS; ENZYME INHIBITORS; LABILE MOLECULES; PH CONTROL; PRODRUGS; REANALYSIS; STABILITY ASSESSMENT;

ESTERS;

EID: 85019327183     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118671276.ch34     Document Type: Chapter

References (44)

1. Aldrige WN. Serum esterases. Biochem J 1952;53:110-117.
2. Bergeron M, Bergeron A, Furtado M, Garofolo F. Impact of plasma and whole-blood anticoagulant counter ion choice on drug stability and matrix effects during bioanalysis. Bioanalysis 2009;1(3):537-548.
3. Bergmann F, Segal R, Rimon S. A new type of esterase in hogkidney extract. Biochem J 1957;67(3):481-486.
4. Briscoe CJ, Hage DS. Factors affecting the stability of drugs and drug metabolites in biological matrices. Bioanalysis 2009;1(1):205-220.
5. Cao YG, Zhang M, Yu D, Shao JP, Chen YC, Liu XQ. A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study. Anal Bioanal Chem 2008;391(3):1063-1071.
6. Chang Q, Chow MS, Zuo Z. Studies on the influence of esterase inhibitor to the pharmacokinetic profiles of oseltamivir and oseltamivir carboxylate in rats using an improved LC/MS/MS method. Biomed Chromatogr 2009;23(8):852-857.
7. Chen J, Hsieh Y. Stabilizing drug molecules in biological samples. Ther Drug Monit 2005;27(5):617-624.
8. D'Arienzo CJ, Ji QC, Discenza L, et al. DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors. Bioanalysis 2010;2(8):1415-1422.
9. Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem 2001;34(2):107-112.
10. Freisleben A, Brudny-Klöppel M, Mulder H, de Vries R, de Zwart M, Timmerman P. Blood stability testing: European bioanalysis forum view on current challenges for regulated bioanalysis. Bioanalysis 2011;3(12):1333-1336.
11. Fung EN, Zheng N, Arnold ME, Zeng J. Effective screening approach to select esterase inhibitors used for stabilizing ester-containing prodrugs analyzed by LC-MS/MS. Bioanalysis 2010;2(4):733-743.
12. Heinig K, Wirz T, Bucheli F, Gajate-Perez A. Determination of oseltamivir (Tamiflu-R) and oseltamivir carboxylate in dried blood spots using offline or online extraction. Bioanalysis 2011;3(4):421-437.
13. Ishizuka T, Fujimori I, Kato M, et al. Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine. J Biol Chem 2010;285(16):11892-11902.
14. Kamei T, Uchimura T, Nishimiya K, Kawanishi T. Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC-MS/MS, and its application in a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879(30):3415-3422.
15. Kim MS, Song JS, Roh H, et al. Determination of a peroxisome proliferator-activated receptor γ agonist, 1-(transmethylimino-N-oxy)-6-(2-morpholinoethoxy-3-phenyl-1Hindene-2-carboxylic acid ethyl ester (KR-62980) in rat plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2011;54(1):121-126.
16. Koitka M, Höchel J, Gieschen H, Borchert HH. Improving the ex vivo stability of drug ester compounds in rat and dog serum: inhibition of the specific esterases and implications on their identity. J Pharm Biomed Anal 2010;51(3):664-678.
17. Kromdijk W, Rosing H, van den Broek MP, Beijnen JH, Huitema AD. Quantitative determination of oseltamivir and oseltamivir carboxylate in human fluoride EDTA plasma including the ex vivo stability using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2012;891-892:57-63.
18. Kudo S, Umehara K, Hosokawa M, Miyamoto G, Chiba K, Satouh T. Phenacetin deacetylase activity in human liver microsomes: distribution, kinetics, and chemical inhibition and stimulation. J Pharmacol Exp Ther 2000;294(1):80-87.
19. Li W, Tse FL. Dried blood spot sampling in combination with LCMS/MS for quantitative analysis of small molecules. Biomed Chromatogr 2010;24(1):49-65.
20. Li W, Zhang J, Tse FL. Strategies in quantitative LC-MS/MS analysis of unstable small molecules in biological matrices. Biomed Chromatogr 2011;25(1-2):258-277.
21. Liederer BM, Borchardt RT. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diasteromeric opioid peptides in biological media from various animal species including human. J Pharm Sci 2005;94(10):2198-2206.
22. Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 2006;95(6):1177-1195.
23. Lindegardh N, Davies GR, Tran TH, et al. Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob Agents Chemother 2006;50(9):3197-3199.
24. Meng M, Reuschel S, Bennett P. Identifying trends and developing solutions for incurred sample reanalysis failure investigations in a bioanalytical CRO. Bioanalysis 2011;3(4):449-465.
25. Minagawa T, Kohno Y, Suwa T, Tsuji A. Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem Pharmacol 1995;49(10):1361-1365.
26. Olivera-Bravo S, Ivorra I, Morales A. The acetylcholinesterase inhibitor BW284c51 is a potent blocker of Torpedo nicotinic AchRs incorporated into the Xenopus oocyte membrane. Br J Pharmacol 2005;144(1):88-97.
27. Peterson LW, McKenna CE. Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues. Expert Opin Drug Deliv 2009;6(4):405-420.
28. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008;7(3):255-270.
29. Rooseboom M, Commandeur JN, Vermeulen NP. Enzymecatalyzed activation of anticancer prodrugs. Pharmacol Rev 2004;56(1):53-102.
30. Salem II, Alkhatib M, Najib N. LC-MS/MS determination of betamethasone and its phosphate and acetate esters in human plasma after sample stabilization. J Pharm Biomed Anal 2011;56(5):983-991.
31. Skopp G, Klingmann A, Pötsch L, Mattern R. In vitro stability of cocaine in whole blood and plasma including ecgonine as a target analyte. Ther Drug Monit 2001;23(2):174-181.
32. Stella VJ, Charman WN, Naringrekar VH. Prodrugs: Do they have advantages in clinical practice? Drugs 1985;29(5):455-473.
33. Tang C, Sojinu OS. Simultaneous determination of caffeic acid phenethyl ester and its metabolite caffeic acid in dog plasma using liquid chromatography tandem mass spectrometry. Talanta 2012;94:232-239.
34. Tokumura T, Muraoka A, Masutomi T, Machida Y. Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. Biol Pharm Bull 2005;28(6):1126-1128.
35. Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H. In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica 2009;39(5):391-398.
36. Wang X, Bowman PD, Kerwin SM, Stavchansky S. Stability of caffeic acid phenethyl ester and its fluorinated derivative in rat plasma. Biomed Chromatogr 2007;21(4):343-350.
37. Welch RM, Brown A, Ravitch J, Dahl R. The in vitro degradation of cisatracurium, the R, cis-R_-isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995;58(2):132-142.
38. Wiltshire H, Wiltshire B, Citron A, et al. Development of a highperformance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl 2000;745(2):373-388.
39. Yamaori S, Fujiyama N, Kushihara M, et al. Involvement of human blood arylesterase and liver microsomal carboxylesterase in nafamostat hydrolysis. Drug Metab Pharmacokinet 2006;21(2):147-155.
40. Yang JZ, Chen W, Borchardt RT. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-DAla-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs. J Pharmacol Exp Ther 2002;303(2):840-848.
41. Yoshigae Y, Imai T, Taketani M, Otagiri M. Characterization of esterases involved in the steroselective hydrolysis of estertype prodrugs of propranolol in rat liver and plasma. Chirality 1999;11:10-13.
42. Zeng J, Onthank D, Crane P, et al. Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometry-evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile estercontaining drug. J Chromatogr B Analyt Technol Biomed Life Sci 2007;852(1-2):77-84.
43. Zhang JG, Fariss MW. Thenoyltrifluoroacetone, a potent inhibitor of carboxylesterase activity. Biochem Pharmacol 2002;63:751-754.
44. Zhang Y, Tingley FD 3rd, Tseng E, et al. Development and validation of a sample stabilization strategy and a UPLCMS/MS method for the simultaneous quantitation of acetylcholine (ACh), histamine (HA), and its metabolites in rat cerebrospinal fluid (CSF). J Chromatogr B Analyt Technol Biomed Life Sci 2011;879(22):2023-2033.